Industry
Biotechnology
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Loading...
Open
1.41
Mkt cap
1.9M
Volume
180K
High
1.41
P/E Ratio
-0.12
52-wk high
666.00
Low
1.33
Div yield
N/A
52-wk low
1.26
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 1:57 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 12:55 pm
Portfolio Pulse from Benzinga Newsdesk
September 11, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:50 pm
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 2:41 pm
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Newsdesk
August 30, 2024 | 8:08 pm
Portfolio Pulse from Benzinga Newsdesk
August 30, 2024 | 7:44 pm
Portfolio Pulse from Benzinga Newsdesk
August 29, 2024 | 8:01 pm
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 1:03 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.